CI

At a glance

ClinicalIndex Comparison Record
N/ACompleted· 9 enrolled
Drug / intervention
Blood samples before and after standard of care of polymyalgia rheumaticaother
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT05681676
NCT05681676N/ACompleted
CompareCT.gov

Is the Melanocortin System Involved in Inflammatory Resolution

Aalborg University·observational·Posted Jan 12, 2023·Updated Jan 12, 2023

In Brief

An observational study evaluating Blood samples before and after standard of care of polymyalgia rheumatica for Polymyalgia Rheumatica. Completed, enrolled 9 participants.

Detailed Summary

Polymyalgia rheumatica (PMR) is a systemic inflammatory disorder with unknown etiology and overlapping symptoms with giant cell arthritis and rheumatoid arthritis (RA). The proteomic profile of PMR patients remains uncharacterized and biomarker studies very limited. The primary aim of this study was to thoroughly investigate the lymphocyte expression of melanocortin receptors, and the serum proteome during glucocorticoid treatment of PMR with a focus on acute-phase reactions, the complement system, and pro-inflammatory cytokines.

Study Details

Study Typeobservational
Allocation--
Masking--
Primary Purpose--
ConditionsPolymyalgia Rheumatica
Countries--
Collaborators--

Timeline

N/ACompletedFinished
201220132014201520162017201820192020202120222023202420252026
First PostedJan 12, 2023
Enrollment StartMar 1, 2012
Primary CompletionDec 1, 2015
Study CompletionDec 1, 2022
TodayJul 2, 2026
Enrollment to primary: 3.8 yearsPosted 3.5 years ago

Interventions

Blood samples before and after standard of care of polymyalgia rheumaticaother

Blood samples were taken before glucocorticoid treatment and three months after.